Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176,627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Ren Z, et al. Among authors: chen z, chen m, chen y. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143971 Clinical Trial.
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Ye SL, et al. Among authors: chen x, chen y. Oncotarget. 2016 Feb 9;7(6):6639-48. doi: 10.18632/oncotarget.6781. Oncotarget. 2016. PMID: 26735891 Free PMC article. Clinical Trial.
Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.
Zhao H, Zhou A, Zhou J, Bi X, Yan S, Jin J, Wei W, Li M, Gong C, Chen Q, Luo Z, Li N, Mao R, Chen X, Chen B, Zheng R, Zhao J, Han Y, Li Z, Che X, Tang Y, Sun Y, Huang Z, Zhang Y, Wang X, Zhang Y, Lu Z, Dang X, Song T, Liu C, Yue P, Yan D, Yue A, Zhang R, Luo S, Tan J, Zhang X, Bai X, Zhang X, He M, Xie Y, Wang W, Yang P, Yang Y, Zhang Y, Li Q, Peng T, Wang Z, Chen Y, Shang C, Liang Y, Zhang B, Zhang F, Wang L, Li D, Liu B, Zhu X, Hu Q, Chen M, Xiu D, Xia F, Zhang Y, Zeng Y, Mao Y, Li X, Ba Y, Liang T, Shen F, Liu L, Cai X, Zhou J, Cai J. Zhao H, et al. Among authors: chen m, chen q, chen b, chen x, chen y. HPB (Oxford). 2022 Mar;24(3):342-352. doi: 10.1016/j.hpb.2021.07.002. Epub 2021 Jul 26. HPB (Oxford). 2022. PMID: 34400051 Free PMC article.
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).
Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W, Zhao M, Bi X, Li G, Bai X, Ji Y, Xu L, Zhu XD, Bai D, Chen Y, Chen Y, Dai C, Guo R, Guo W, Hao C, Huang T, Huang Z, Li D, Li G, Li T, Li X, Li G, Liang X, Liu J, Liu F, Lu S, Lu Z, Lv W, Mao Y, Shao G, Shi Y, Song T, Tan G, Tang Y, Tao K, Wan C, Wang G, Wang L, Wang S, Wen T, Xing B, Xiang B, Yan S, Yang D, Yin G, Yin T, Yin Z, Yu Z, Zhang B, Zhang J, Zhang S, Zhang T, Zhang Y, Zhang Y, Zhang A, Zhao H, Zhou L, Zhang W, Zhu Z, Qin S, Shen F, Cai X, Teng G, Cai J, Chen M, Li Q, Liu L, Wang W, Liang T, Dong J, Chen X, Wang X, Zheng S, Fan J; Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association. Sun HC, et al. Among authors: chen m, chen x, chen y. Hepatobiliary Surg Nutr. 2022 Apr;11(2):227-252. doi: 10.21037/hbsn-21-328. Hepatobiliary Surg Nutr. 2022. PMID: 35464283 Free PMC article. Review.
176,627 results
You have reached the last available page of results. Please see the User Guide for more information.